Adaptive radiation therapy for advanced pancreatic cancer
Part of Cancer clinical trials.
This trial tests a new way of giving radiation therapy that adapts to changes in your cancer over time. It is for people with pancreatic cancer that cannot be removed by surgery but has not spread to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of pancreatic cancer called pancreatic ductal adenocarcinoma, confirmed by a biopsy.
- Your cancer must be locally advanced, meaning it cannot be removed safely with surgery.
- You must not have cancer that has spread to other organs (metastatic disease).
- You must be at least 18 years old and in fairly good health (able to care for yourself, at least up and about more than half the day).
- You must not have had radiation therapy for pancreatic cancer before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that uses tiny alpha radiation sources placed directly into the tumor to destroy cancer cells. It is for people with pancreatic cancer that has not spread but cannot be removed surgically, and who have already tried at least one type of chemotherapy or cannot take more chemo.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
This trial tests a new type of radiation called DaRT (Alpha DaRT) combined with standard chemotherapy for people with pancreatic cancer that is locally advanced or has spread. The goal is to see if adding this radiation treatment can help shrink tumors or slow the cancer's growth.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
This trial tests a special, high-dose radiation treatment for pancreatic cancer that has not spread but cannot be removed with surgery. The goal is to shrink the tumor and improve control of the cancer in the abdomen.
This trial tests a radiation treatment that places tiny radioactive seeds directly into the tumor to treat advanced pancreatic cancer. It mainly focuses on safety and whether the treatment can be delivered effectively, especially for people who may not be able to have more chemotherapy or surgery.
Hear when a new Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.